GLP-1 Tablets in Czechia (2026): What Is Approved and What Is Coming
Medically reviewed by MUDr. Iveta Novotná, obesitologist
GLP-1 tablets in Czechia: a weight-loss tablet is authorised in the EU and registered here but not yet in pharmacies, and a second awaits a decision (18 Oct 2026).
A GLP-1 tablet for weight management is authorised in the EU, but it is not yet in pharmacies in the Czech Republic. The Wegovy tablet (oral semaglutide) was authorised on 14 July 2026 and is registered here, yet as of 18 October 2026 the Czech regulator SÚKL records no launch. A second tablet, orforglipron, awaits a European Commission decision.
GLP-1 tablets in Czechia: the short answer
- Authorised in the EU: the Wegovy tablet (oral semaglutide, once daily, adults only), by a European Commission decision of 14 July 2026.
- Czechia, as of 18 October 2026: registered and prescription-only, with no start of marketing, price or insurance coverage recorded.
- Coming next: orforglipron has a positive EMA opinion of 15 October 2026; the Commission decision is pending.
- No Mounjaro tablet: EMA lists it as a weekly injection only.
- Online "GLP-1 pills": the registered tablets need a prescription, and SÚKL says any online offer of prescription-only medicines is illegal.
Which GLP-1 tablets are approved in the EU, the UK and the US?
| Tablet | EU | UK | US |
|---|---|---|---|
| Wegovy tablet (oral semaglutide) | Authorised 14 July 2026 | Approved 11 June 2026 | Approved 22 December 2025 |
| Orforglipron (Foundayo) | Positive EMA opinion 15 October 2026, decision pending | Authorised 10 August 2026 | Approved 1 April 2026 |
Status as of 18 October 2026.
The Wegovy tablet is taken once a day on an empty stomach (after at least eight hours without food) with a sip of water, and you then wait 30 minutes before eating, drinking or taking other medicines. The dose rises from 1.5 mg to 25 mg in steps of at least four weeks (EMA product information).
Orforglipron is a small, non-peptide molecule that activates the GLP-1 receptor, taken once daily at any time of day (EMA). EMA's opinion covers adult weight management and type 2 diabetes, and the Commission decision normally follows 67 days after the opinion. Until then it is not authorised in the EU, and the SÚKL database lists no orforglipron product.
When will a weight-loss tablet reach Czech pharmacies?
An EU authorisation applies in every member state, but a medicine reaches pharmacies only after its holder starts supply, which the holder must report to SÚKL. On 18 October 2026 the SÚKL database showed the following for the Wegovy tablet (registration data updated 12 October):
| Question | SÚKL record |
|---|---|
| Registered in Czechia? | Yes: tablets of 1.5, 4, 9 and 25 mg, prescription-only |
| Marketing started? | No report for any tablet pack |
| Price or insurance coverage? | None recorded |
Launch dates differ by country. Euronews reported that Germany became the first EU country with the Wegovy pill in pharmacies, on 1 September 2026, and Novo Nordisk said on 15 July 2026 that it is committed to launching the tablet in more countries in the second half of 2026. We found no date for Czechia at SÚKL or in the company's statements, so we do not estimate one.
Price and reimbursement are also decided by each member state (EMA) and none is recorded here yet, so this article gives no figures. The Wegovy injection, by contrast, is already supplied: SÚKL records the start of marketing for several pen strengths. For injection costs see what weight-loss treatment costs in Czechia, and for supply GLP-1 availability in Czech pharmacies.
How do tablet and injection trial results compare?
We found no weight-loss trial that tested a tablet directly against an injection (PubMed and ClinicalTrials.gov, 18 October 2026), so any comparison is indirect. These four placebo-controlled trials in adults without diabetes differ in length, dose and participants. All added diet and activity advice, all were funded by the manufacturers, and all report the average for everyone randomised, including people who stopped treatment.
| Medicine | Trial (adults) | Weeks | Dose | Average weight change | Placebo |
|---|---|---|---|---|---|
| Wegovy tablet | OASIS 4 (307) | 64 | 25 mg daily | −13.6% | −2.2% |
| Semaglutide injection | STEP 1 (1,961) | 68 | 2.4 mg weekly | −14.9% | −2.4% |
| Orforglipron tablet | ATTAIN-1 (3,127) | 72 | 6, 12 or 36 mg daily | −7.5%, −8.4%, −11.2% | −2.1% |
| Tirzepatide injection | SURMOUNT-1 (2,539) | 72 | 5, 10 or 15 mg weekly | −15.0%, −19.5%, −20.9% | −3.1% |
The ATTAIN-1 doses are trial doses, not the tablet strengths in EMA's opinion. EMA's product information says efficacy and safety were similar in OASIS 4 and STEP 1 regardless of route, but also that the tablet is absorbed with higher variability (bioavailability about 1 to 2%), so the effect of switching between injection and tablet cannot easily be predicted. Averages hide wide individual differences, and which form suits a person is a medical decision. See our comparison of GLP-1 medicines in Czechia and guide to weight-loss injections.
Who are the tablets for, and what are the risks?
The EU indication for the authorised tablet covers adults only: a BMI of 30 or above, or 27 to under 30 with at least one weight-related condition, such as prediabetes, high blood pressure or sleep apnoea. It supplements a reduced-calorie diet and more physical activity and does not replace them, and it should not be used in pregnancy or while breastfeeding (EMA product information). You can check your BMI with our BMI calculator.
Side effects are mainly digestive and most frequent while the dose is rising. In the 64-week OASIS 4 trial, nausea affected 46.6% of people on the tablet and 18.6% on placebo, vomiting 30.9% and 5.9%, constipation 20.1% and 9.8%, and diarrhoea 17.6% and 8.8%; digestive problems made 3.4% stop treatment (EMA product information). The second tablet awaiting approval showed the same pattern, and in ATTAIN-1 side effects led 5.3% to 10.3% of people on it to stop treatment, against 2.7% on placebo. Results differ from person to person and none can be promised. The doctor decides whether treatment is suitable and may decide against it.
How can you start treatment in Czechia as a foreign resident?
Prescription medicines are never posted to patients in Czechia: SÚKL says mail-order dispensing is limited to registered medicines that need no prescription. Treatment starts with an assessment by a licensed doctor, who decides whether it is suitable and, if so, issues an eRecept: an electronic prescription with a unique identifier that the pharmacist loads. You then collect the medicine at a pharmacy.
If you have no registered Czech GP, the route is explained in obesity treatment in Czechia without a GP, and the practical side of the e-prescription in our eRecept guide. If you are already on treatment abroad, see continuing GLP-1 treatment after moving to Czechia.
Do the weekly injections have a tablet version?
Mounjaro (tirzepatide) is a once-weekly injection. EMA describes it as given by prefilled pen; every presentation on its list of authorised presentations is a solution for injection; and the current US label covers injection pens and vials only. As of 18 October 2026 we found no authorised tablet form of tirzepatide in the EU or the US, and the SÚKL database lists it only as injections.
Ozempic is also a weekly injection, authorised for type 2 diabetes. The other semaglutide tablet is Rybelsus, authorised in the EU on 3 April 2020, again for type 2 diabetes only. For the injections, see Wegovy in Czechia, Mounjaro in Czechia and Ozempic in the Czech Republic.
Are online "GLP-1 pills" real medicines?
No prescription-only medicine, including a GLP-1 tablet, can lawfully be offered online in Czechia. A "GLP-1 pill" sold that way is a dietary supplement, which SÚKL says is not a medicine even when it looks like one, or an illegal product. See our guide to illegal online pharmacies in Czechia.
Next step: talk to a doctor
If you are considering medical treatment for overweight or obesity, you can complete a short questionnaire and talk to a licensed Czech doctor online, in English. The doctor explains the options and their risks and decides whether treatment is suitable. The doctor may also decline. All treatment has side effects, and results differ from person to person.
Frequently asked questions
Is there a GLP-1 pill for weight loss in Czechia?
Not yet in pharmacies. The Wegovy tablet (oral semaglutide) has been authorised in the EU since 14 July 2026 and SÚKL, the State Institute for Drug Control, lists it as registered, but as of 18 October 2026 SÚKL records no start of marketing. Rybelsus, a semaglutide tablet authorised since 2020, is for type 2 diabetes only. A second weight-loss tablet, orforglipron, has a positive EMA opinion of 15 October 2026 and awaits the European Commission decision. All are prescription medicines, and the doctor decides whether treatment is suitable.
When will the Wegovy tablet be in Czech pharmacies?
No date is known. A medicine reaches pharmacies once its holder starts supply and reports it to SÚKL; as of 18 October 2026 the SÚKL database shows no such report for the tablet. Euronews reported that Germany was the first EU country to launch it, on 1 September 2026, and Novo Nordisk says more countries will follow in the second half of 2026 without naming Czechia. Price and insurance coverage are decided country by country and none is recorded here yet.
Is there a Mounjaro tablet?
No. As of 18 October 2026 EMA describes Mounjaro (tirzepatide) as a once-weekly injection in prefilled pens, and every authorised presentation is a solution for injection. Semaglutide exists as a tablet under two names: Rybelsus for type 2 diabetes and the Wegovy tablet for weight management.
Are pills as effective as injections?
We cannot say for certain, because we found no weight-loss trial that compared a tablet directly with an injection. In OASIS 4 the Wegovy tablet (25 mg daily) cut body weight by an average of 13.6% over 64 weeks against 2.2% on placebo. In STEP 1 semaglutide injected weekly (2.4 mg) cut it by 14.9% over 68 weeks against 2.4%. In ATTAIN-1 orforglipron (36 mg daily) cut it by 11.2% over 72 weeks against 2.1%. In SURMOUNT-1 tirzepatide (5 to 15 mg weekly) cut it by 15.0% to 20.9% over 72 weeks against 3.1%. These are averages from different trials, and EMA notes that the tablet is absorbed with higher variability than the injection. Results differ from person to person, none can be promised, and the doctor decides what is suitable.
Can I bring GLP-1 tablets from abroad?
SÚKL says mail-order dispensing covers only registered medicines that need no prescription and that any online offer of prescription-only medicines is illegal, and GLP-1 tablets need a prescription, so they cannot lawfully be posted to you or offered online in Czechia. For what you carry yourself, the Czech Customs Administration says medicines from outside the EU may be brought in only in a volume matching ordinary personal need for the length of a trip. That page does not cover medicines carried from other EU countries, so ask SÚKL or customs before you travel.